Harbor Capital Advisors Inc. Cuts Stock Holdings in Perrigo Company plc $PRGO

Harbor Capital Advisors Inc. trimmed its stake in shares of Perrigo Company plc (NYSE:PRGO) by 66.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,444 shares of the company’s stock after selling 38,181 shares during the period. Harbor Capital Advisors Inc.’s holdings in Perrigo were worth $433,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Geneos Wealth Management Inc. grew its position in shares of Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares in the last quarter. Huntington National Bank boosted its stake in Perrigo by 237.8% during the second quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after buying an additional 742 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in Perrigo by 54.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock valued at $32,000 after buying an additional 424 shares in the last quarter. Hantz Financial Services Inc. grew its holdings in Perrigo by 101.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock valued at $33,000 after buying an additional 620 shares in the last quarter. Finally, Kestra Investment Management LLC increased its stake in Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after acquiring an additional 642 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Insider Buying and Selling

In other Perrigo news, Director Geoffrey M. Parker bought 7,500 shares of Perrigo stock in a transaction on Wednesday, November 12th. The shares were acquired at an average price of $14.18 per share, for a total transaction of $106,350.00. Following the completion of the purchase, the director directly owned 17,375 shares in the company, valued at approximately $246,377.50. This trade represents a 75.95% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PRGO shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Wall Street Zen lowered shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Canaccord Genuity Group reduced their target price on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. JPMorgan Chase & Co. lowered their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Finally, Zacks Research lowered Perrigo from a “hold” rating to a “strong sell” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $22.00.

Perrigo Price Performance

Perrigo stock opened at $13.83 on Monday. Perrigo Company plc has a 12-month low of $12.17 and a 12-month high of $30.93. The company has a current ratio of 2.51, a quick ratio of 1.44 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average price of $15.39 and a 200-day moving average price of $21.23. The firm has a market capitalization of $1.90 billion, a PE ratio of -36.38 and a beta of 0.39.

Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.10 billion. Perrigo had a negative net margin of 1.21% and a positive return on equity of 9.16%. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.81 EPS. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. As a group, equities research analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 16th. Investors of record on Friday, November 28th were issued a dividend of $0.29 per share. The ex-dividend date was Friday, November 28th. This represents a $1.16 dividend on an annualized basis and a yield of 8.4%. Perrigo’s payout ratio is presently -305.26%.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.